Effects of Consolidation Therapy With Autologous Hematopoietic Stem Cell Transplantation After BCMA-CAR T-Cell Therapy on the Survival of Patients With Relapsed or Refractory Multiple Myeloma

Zhou, Ziwei; Liu, Xuan; Zhang, Xuejun; Wen, Shupeng; Hua, Huan; Xu, Zheng; Wang, Fuxu

doi:10.1016/j.jtct.2024.08.024

Transplantation and Cellular Therapy

2024

DOI: 10.1016/j.jtct.2024.08.024

|View full text |Cite

Effects of Consolidation Therapy With Autologous Hematopoietic Stem Cell Transplantation After BCMA-CAR T-Cell Therapy on the Survival of Patients With Relapsed or Refractory Multiple Myeloma

Ziwei Zhou,

Xuan Liu,

Xuejun Zhang

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Recent Advances in the Treatment of Multiple Myeloma in the Era of New Drug Development

Hu,

Xiang

2024

Asp Biomed Clin Case Rep

View full text Add to dashboard Cite

Multiple myeloma (MM) is a malignant hematologic disease characterized by the neoplastic proliferation of plasma cells in the bone marrow. It exhibits high heterogeneity, a tendency for relapse, and resistance to treatment. The primary goal of first-line therapy is to achieve deep remission and durable disease control. Current conventional treatment approaches can improve patient prognosis but have significant limitations. The emergence of novel therapies, including proteasome inhibitors, immunomodulatory agents, monoclonal antibodies, chimeric antigen receptor T-cell therapy, and immune checkpoint inhibitors, marks a new era in MM treatment. However, due to the relapsed and refractory nature of MM, future applications should consider various factors and tailor treatment strategies to individual circumstances to optimize therapeutic efficacy.

show abstract

Recent Advances in the Treatment of Multiple Myeloma in the Era of New Drug Development

Hu,

Xiang

2024

Asp Biomed Clin Case Rep

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Effects of Consolidation Therapy With Autologous Hematopoietic Stem Cell Transplantation After BCMA-CAR T-Cell Therapy on the Survival of Patients With Relapsed or Refractory Multiple Myeloma

Cited by 1 publication

References 36 publications

Recent Advances in the Treatment of Multiple Myeloma in the Era of New Drug Development

Recent Advances in the Treatment of Multiple Myeloma in the Era of New Drug Development

Contact Info

Product

Resources

About